https://www.selleckchem.com/products/azd-5462.html
The half-life of the GLP-HFt nanocage was approximately 52 h in mice after subcutaneous injection. The prolonged half-life and sustained control of blood glucose levels indicate that the GLP-HFt nanocage can be further developed for the treatment of T2DM. Meanwhile, the HFt nanocage proves its great potential as a universal carrier that improves the pharmacodynamic and pharmacokinetic properties of a wide range of therapeutic peptides and proteins.We report a powerful strategy, iridium-catalyzed direct C-H amidation (DCA) for synthesiz
Like
Comment
Share
